HopeStage
Back to all studies
RecruitingNCT05669742

Empagliflozin for metabolic changes linked to olanzapine in schizophrenia

About this titleRead the official source — NCT05669742

This study evaluates the safety and effectiveness of Empagliflozin for people with schizophrenia.

Medication studyAges 18–65Egypt
The study in practice

Understand this study

What is this study about?

This study evaluates the safety and effectiveness of Empagliflozin for people with schizophrenia.

Who could participate?

Listed age limits: 18 years to 65 years.

Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 25, 2023
Recruitment status
Recruiting
Enrollment listed in the registry
40
Sponsor
Tanta University
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Egypt
Age range
From 18 Years to 65 Years
Official registry ID
NCT05669742
Official title
Show the full official title

Evaluating the Safety and Efficacy of Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients.A Double-Blind, Randomized, Placebo-Controlled Trial

Recruitment & locations

Currently recruiting

Tanta

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

This study evaluates the safety and effectiveness of Empagliflozin for people with schizophrenia.

Who is behind this study?

The study sponsor is Tanta University, a university.

Does this study involve medication?

Yes. The study involves medication, including Empagliflozin and olanzapine.

Who can participate?

Listed age limits: 18 years to 65 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies